Technical Analysis for IBRX - ImmunityBio, Inc.

Grade Last Price % Change Price Change
F 16.43 8.59% 1.30
IBRX closed up 4.63 percent on Friday, May 14, 2021, on 81 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical IBRX trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bearish Bearish Swing Setup 8.59%
Lower Bollinger Band Walk Weakness 8.59%
Inside Day Range Contraction 8.59%
Wide Bands Range Expansion 8.59%
Lower Bollinger Band Touch Weakness 8.59%
Oversold Stochastic Weakness 8.59%
200 DMA Resistance Bearish 13.62%
Expansion Breakdown Bearish Swing Setup 13.62%
Stochastic Reached Oversold Weakness 13.62%
Wide Bands Range Expansion 13.62%
Older End-of-Day Signals for IBRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Resistance about 2 hours ago
Rose Above 20 DMA about 2 hours ago
60 Minute Opening Range Breakout about 2 hours ago
Up 10% about 2 hours ago
Up 1 ATR about 2 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ImmunityBio, Inc. Description

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Infectious Diseases Immunotherapy Cancer Immunotherapy Cancer Treatments Virotherapy Genomics Natural Killer Cell Lymphocytes Pelareorep

Is IBRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 45.42
52 Week Low 4.46
Average Volume 1,216,340
200-Day Moving Average 15.53
50-Day Moving Average 22.89
20-Day Moving Average 17.08
10-Day Moving Average 16.01
Average True Range 1.64
ADX 23.56
+DI 16.46
-DI 31.27
Chandelier Exit (Long, 3 ATRs ) 14.80
Chandelier Exit (Short, 3 ATRs ) 18.91
Upper Bollinger Band 19.82
Lower Bollinger Band 14.33
Percent B (%b) 0.15
BandWidth 32.11
MACD Line -1.77
MACD Signal Line -1.89
MACD Histogram 0.1181
Fundamentals Value
Market Cap 1.64 Billion
Num Shares 109 Million
EPS -0.89
Price-to-Earnings (P/E) Ratio -16.94
Price-to-Sales 9386.43
Price-to-Book 6.72
PEG Ratio 2.56
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.83
Resistance 3 (R3) 16.73 16.06 16.54
Resistance 2 (R2) 16.06 15.63 16.11 16.45
Resistance 1 (R1) 15.60 15.36 15.83 15.70 16.35
Pivot Point 14.93 14.93 15.05 14.98 14.93
Support 1 (S1) 14.47 14.50 14.70 14.57 13.91
Support 2 (S2) 13.80 14.23 13.85 13.81
Support 3 (S3) 13.34 13.80 13.72
Support 4 (S4) 13.44